Egypt’s Hepatitis C Program: A Model for Africa’s Health Initiatives

By Crystal Lubbe

December 12, 2024

The article from the Africa CDC website, titled “Egypt’s Hepatitis Programme Becomes a Model for African Countries,” highlights Egypt’s successful hepatitis C elimination program, which serves as a benchmark for other African countries. By implementing the “100 Million Healthier Lives” campaign, Egypt has achieved Gold-tier certification for its progress toward eliminating hepatitis C, as recognised by the World Health Organization (WHO). This remarkable achievement showcases how effective public health initiatives can lead to significant health improvements across the continent.

Egypt’s Hepatitis C Elimination Program

Egypt Hepatitis C Program has benefited its citizens and set a powerful example for other African nations. Notably, the country has made significant strides in training and capacity building.

Training and Capacity Building

The Africa CDC, in collaboration with Egypt’s Ministry of Health and Population, has implemented training programs for experts from various African Union member states. These programs are designed to equip participants with the necessary skills to launch “screen-and-treat” programs for hepatitis C. To date, 26 members have been trained, with an additional cohort of 31 participants from multiple African countries completing their training in November 2024.

Regional Collaboration and Support

Moreover, Egypt plays a pivotal role by providing technical support, screening software, and free treatment for one million people in 14 African nations. This collaborative effort aligns with WHO screening and treatment guidelines.

Best Practices and Challenges

The training includes lectures, field trips, and discussions on best practices and challenges in hepatitis elimination. Participants visit hospitals, healthcare settings, and pharmaceutical companies to understand Egypt’s comprehensive strategy.

Africa CDC’s Role

The Africa CDC is actively supporting African nations by funding seroprevalence surveys, providing necessary kits and drugs, and training health workers. For example, Madagascar is currently undergoing a capacity and readiness assessment for viral hepatitis elimination, as part of the support provided by the Africa CDC.

South-South Cooperation

The initiative promotes South-South cooperation, encouraging shared learning and collaboration to improve public health outcomes continent-wide. This approach is a cornerstone of Egypt’s hepatitis C elimination successes and its potential replicability in other African countries.

Action Plans and Future Initiatives

Country representatives create action plans to apply training and identify needed support from Africa CDC and Egypt. For example, Cameroon is poised to launch a Triple elimination strategy, guided by the training and support it has received.

Conclusion

Egypt Hepatitis C Program stands as a model for other African countries. Notably thanks to its comprehensive approach, innovative financing, and political commitment. The program’s achievements signal a promising pathway toward the global goal of eliminating viral hepatitis by 2030. With continued regional collaboration and strong action plans, the impact of Egypt’s efforts will undoubtedly resonate across the continent.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.